RESISTANCE TO TARGETED THERAPIES IN MELANOMA: NEW INSIGHTS

Several molecular mechanisms are involved in melanoma genesis and progression. Molecular targets for effective therapeutic intervention have been identified within the RAS-RAF-MEK-ERK and, to a less extent, PI3K-AKT pathways. The development of inhibitors of key effectors (mainly BRAF mutant, MEK, a...

Full description

Saved in:
Bibliographic Details
Main Authors: Giuseppe Palmieri (Author), Maria Colombino (Author), Maria Cristina Sini (Author), Antonella Manca (Author), Paolo Antonio Ascierto (Author), Antonio Cossu (Author)
Format: Book
Published: European Medical Journal, 2013-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_72645bd0c7e44e48a6ea8013ec4db0a3
042 |a dc 
100 1 0 |a Giuseppe Palmieri  |e author 
700 1 0 |a Maria Colombino  |e author 
700 1 0 |a Maria Cristina Sini  |e author 
700 1 0 |a Antonella Manca  |e author 
700 1 0 |a Paolo Antonio Ascierto  |e author 
700 1 0 |a Antonio Cossu  |e author 
245 0 0 |a RESISTANCE TO TARGETED THERAPIES IN MELANOMA: NEW INSIGHTS 
260 |b European Medical Journal,   |c 2013-12-01T00:00:00Z. 
500 |a 2054-6211 
500 |a 2054-6211 
520 |a Several molecular mechanisms are involved in melanoma genesis and progression. Molecular targets for effective therapeutic intervention have been identified within the RAS-RAF-MEK-ERK and, to a less extent, PI3K-AKT pathways. The development of inhibitors of key effectors (mainly BRAF mutant, MEK, and KIT) into such pathways has significantly improved the treatment of patients with advanced melanoma. However, emerging data indicate that a large variety of acquired and intrinsic mechanisms may drive resistance to the main targeted inhibitors. All the evidence suggests that in melanoma, as probably in all types of cancer, it is unlikely that targeting a single component in pathogenetic signalling pathways could yield significant antitumour responses. Therefore, knowledge of the multiple altered signalling events involved in response and resistance to targeted treatments will allow for the development of more effective combination therapies, which may represent the next challenge for the management of patients with such a disease 
546 |a EN 
690 |a malignant melanoma 
690 |a molecular pathogenesis 
690 |a targeted therapy 
690 |a braf/mek/kit inhibitors 
690 |a drug resistance 
690 |a Dermatology 
690 |a RL1-803 
655 7 |a article  |2 local 
786 0 |n European Medical Journal Dermatology, Vol 1, Iss 1, Pp 24-37 (2013) 
787 0 |n https://emj.emg-health.com/wp-content/uploads/sites/2/2013/12/Resistance-to-Targeted-Therapies-in-Melanoma-New-Insights.pdf 
787 0 |n https://doaj.org/toc/2054-6211 
787 0 |n https://doaj.org/toc/2054-6211 
856 4 1 |u https://doaj.org/article/72645bd0c7e44e48a6ea8013ec4db0a3  |z Connect to this object online.